PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

An FDA-backed metric used to determine effectiveness of rectal cancer drugs may be unreliable, says new study

The study finds clinical trials for rectal cancer treatments may be fast-tracking drugs for approval without evidence of longer survival

2025-07-17
(Press-News.org) A new study by a Tulane University researcher casts doubt on a widely used shortcut in rectal cancer drug trials, raising concerns that some treatments may be fast-tracked for approval without evidence they help patients live longer.

The study, published in JAMA Network Open in collaboration with researchers at Mayo Clinic in Arizona, found that the absence of detectable tumors after treatment – a key metric in clinical cancer drug trials known as pathologic complete response or pCR – does not reliably predict an improvement in long-term survival for patients diagnosed with rectal cancer.

Traditionally, success of treatments for these patients was determined by measuring “overall survival,” or the years between a person’s diagnosis and death. Since 2012, the U.S. Food and Drug Administration has allowed pharmaceutical companies to use tumor-free status post-therapy as a surrogate for overall survival to cut down on time and expenses needed to approve new cancer treatments.

The researchers conducted a meta-analysis of 25 clinical trials involving nearly 12,000 rectal cancer patients. They found no statistical relationship between pCR and overall survival, meaning cancer drugs may be moving toward development without showing meaningful long-term improvements over existing treatments, said first author Kavin Sugumar, chief resident of general surgery at Tulane University School of Medicine.

“This is about patient outcomes, but it’s also about how we evaluate whether a new drug works,” Sugumar said. “The FDA has approved pCR as a substitute for a result that would normally take years to determine, but we found that pCR should not be used as a sole endpoint to determine if a cancer treatment has been effective.”

PCR remains vital for effectively determining if cancer has been cleared locally from tissue, and patients whose tumors disappear often fare better than those who don’t.

Still, the metric may fail to capture the full picture, such as whether the patient has lingering toxicity from chemotherapy or undetected cancer cells elsewhere in the body.

The use of pCR as a gold standard for drug approval may also increase costs for drug companies which may invest in approved therapies that cannot guarantee improved survival rates.

“Overall survival is a costly and time-consuming endpoint to determine, and I don’t think we’ve found the ideal surrogate yet,” Sugumar said. “Instead of relying solely on pCR, we should maybe include a combination of surrogate endpoints that also includes pCR.”

END


ELSE PRESS RELEASES FROM THIS DATE:

Research Spotlight: evaluating the effectiveness of guidelines to predict the risk of preeclampsia

2025-07-17
Q: How would you summarize your study for a lay audience? Dr. McElrath: Preeclampsia (PE) is a hypertensive disease that complicates 7-10% of pregnancies. While recent advances in understanding the underlying causes of PE have been made, predicting its occurrence has historically been difficult because it is a complex condition that likely results from a variety of causes and can present in different ways. To address this challenge, the United States Preventive Services Task Force (USPSTF) reviewed ...

Pigment researchers create vivid yellows, oranges, reds that are durable, non-toxic

2025-07-17
CORVALLIS, Ore. – Oregon State University pigment researchers are using a rare mineral discovered in Norway more than a century ago as a road map for creating new yellows, oranges and reds that are vibrant, durable, non-toxic and inexpensive. The new pigments also carry energy-saving potential: Their ability to reflect heat from the sun means that buildings and vehicles coated in them will require less air conditioning. The study led by Mas Subramanian, who made color history in 2009 with the discovery of a vivid blue pigment now known commercially as YInMn Blue, was published in Chemistry of Materials. Funded by the National Science Foundation, ...

Increased transparency about how countries use AI to manage migration needed, new study shows

2025-07-17
Increased transparency from countries about how they use AI to manage migration is needed to boost trust and strengthen the rule of law, a new study says. Any overuse of AI in migration management may perpetuate biases and errors, promoting excessive reliance on technology and undermining trust in decision‑making processes, an expert has warned. Adequate cybersecurity measures are also needed to protect sensitive data about vulnerable migrants. However, using AI for migrant management could present opportunities such as freeing up caseworkers’ time to focus on other critical areas, ...

Scientists repurpose old solar panels to convert CO2 exhaust into valuable chemicals

2025-07-17
Centuries ago, alchemists worked furiously to convert the common metal lead to valuable gold. Today, chemists are repurposing discarded solar panels to create valuable organic compounds from carbon dioxide (CO2), a common greenhouse gas. Significantly reducing greenhouse gasses in the atmosphere to mitigate the most devastating effects of climate change will require a large reduction in emissions as well as strategies designed to sequester emitted CO2 and other offending gasses. While simply sequestering ...

Epidemiology: Key predictors of avian flu outbreaks in Europe identified

2025-07-17
Several local factors — including the minimum temperature reached in autumn, the water level in lakes and ponds in winter, and the presence of mute swans (Cygnus olor) — could be key for predicting the potential of an outbreak of highly pathogenic avian flu (HPAI) occurring in Europe. The findings, published in Scientific Reports, are derived from a machine learning model trained on the characteristics of 21st century European HPAI outbreaks and could help improve future monitoring programmes. HPAI outbreaks are a serious concern for both animal and public health. A wave of HPAI outbreaks across the Northern Hemisphere during 2022 were associated with an ...

Global rise in many Early-Onset GI cancers detailed in two Dana-Farber reviews, with colorectal cancer leading the trend

2025-07-17
Boston, MA – July 17, 2025 – Early-onset gastrointestinal (GI) cancers are rising at alarming rates worldwide and, in the U.S., are increasing faster than any other type of early-onset cancer, including breast cancer, according to two recent literature reviews from Dana-Farber Cancer Institute. "Early-Onset Gastrointestinal Cancers: A Review," published today in JAMA, provides a comprehensive analysis of the incidence, risk factors, and treatment approaches for early-onset GI cancers. Authors note the rising rate goes ...

Cancer: COVID-19 boosters prevent hospitalizations

2025-07-17
Vaccine boosters help keep cancer patients from being hospitalized or admitted to intensive care units due to COVID-19, according to a new study led by Cedars-Sinai investigators. Their findings, published in JAMA Oncology, offer real-world evidence to support vaccine recommendations for these patients. “Cancer patients are a vulnerable population,” said Jane Figueiredo, PhD, director of Community Health and Population Research at Cedars-Sinai and senior author of the study. “Their immune systems can be weakened by their disease and the treatments they receive, ...

COVID-19 vaccine booster uptake and effectiveness among US adults with cancer

2025-07-17
About The Study: In this retrospective cohort study, COVID-19 booster vaccinations were associated with significant protection against severe COVID-19, with a favorable number needed to vaccinate among persons with cancer. However, uptake of COVID-19 vaccine boosters was low, and interventions are therefore justified to increase COVID-19 vaccine uptake in this high-risk population. Corresponding Author: To contact the corresponding author, Jacek Skarbinski, MD, email jacek.skarbinski@kp.org. To access the ...

Cannabis use and benign salivary gland neoplasms

2025-07-17
About The Study: The results of this study suggest an association between cannabis use disorder and benign salivary gland tumors. Future prospective research with large samples and data on cannabis dosing, method of use, and benign salivary gland neoplasm pathology is required to further assess and confirm this association. Corresponding Author: To contact the corresponding author, Niels C. Kokot, MD, email niels.kokot@med.usc.edu. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jamaoto.2025.1955) Editor’s ...

Public perception of physicians who use AI

2025-07-17
About The Study: In line with prior research, the results of this study indicate that the public has certain reservations about the integration of artificial intelligence (AI) in health care. While the present effect sizes are relatively small, in particular regarding AI use for administrative purposes, they may be highly relevant as trust in health care practitioners is closely linked to subjective treatment outcomes.  Corresponding Author: To contact the corresponding author, Moritz Reis, MSc, email moritz.reis@uni-wuerzburg.de. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jamanetworkopen.2025.21643) Editor’s ...

LAST 30 PRESS RELEASES:

Long-term anticoagulation discontinuation after catheter ablation for atrial fibrillation

Fractional flow reserve–guided complete vs culprit-only revascularization in non–ST-elevation myocardial infarction and multivessel disease

Participation of women in cardiovascular trials from 2017 to 2023

Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction

Changes in biology of internal fat may be the leading cause of heart failure

Transcatheter or surgical treatment of patients with aortic stenosis at low to intermediate risk

Promising new drug for people with stubborn high blood pressure

One shot of RSV vaccine effective against hospitalization in older adults for two seasons

Bivalent RSV prefusion F protein–based vaccine for preventing cardiovascular hospitalizations in older adults

Clonal hematopoiesis and risk of new-onset myocarditis and pericarditis

Risk of myocarditis or pericarditis with high-dose vs standard-dose influenza vaccine

High-dose vs standard-dose influenza vaccine and cardiovascular outcomes in older adults

Prevalence, determinants, and time trends of cardiovascular health in the WHO African region

New study finds that, after a heart attack, women have worse prognosis when treated with beta-blockers

CNIC-led REBOOT clinical trial challenges 40-year-old standard of care for heart attack patients

Systolic blood pressure and microaxial flow pump–associated survival in infarct-related cardiogenic shock

Beta blockers, the standard treatment after a heart attack, may offer no benefit for heart attack patients and women can have worse outcomes

High Mountain Asia’s shrinking glaciers linked to monsoon changes

All DRII-ed up: How do plants recover after drought?

Research on stigma says to just ‘shake it off’

Scientists track lightning “pollution” in real time using NASA satellite

Millions of women rely on contraceptives, but new Rice study shows they may do more than just prevent pregnancy

Hot days make for icy weather, Philippine study finds

Roxana Mehran, MD, receives the most prestigious award given by the European Society of Cardiology

World's first clinical trial showing lubiprostone aids kidney function

Capturing language change through the genes

Public trust in elections increases with clear facts

Thawing permafrost raised carbon dioxide levels after the last ice age

New DNA test reveals plants’ hidden climate role

Retinitis pigmentosa mouse models reflect pathobiology of human RP59

[Press-News.org] An FDA-backed metric used to determine effectiveness of rectal cancer drugs may be unreliable, says new study
The study finds clinical trials for rectal cancer treatments may be fast-tracking drugs for approval without evidence of longer survival